References
- Zarranz-Ventura J, Mali JO. Effectiveness of 190 µg fluocinolone acetonide and 700 µG dexamethasone intravitreal implants in diabetic macular edema using the area-under-the-curve method: the constant analysis. Clin Ophthalmol. 2020;14:1697–1704. doi:10.2147/OPTH.S253370
- Bellocq D, Akesbi J, Matonti F, et al. The pattern of recurrence in diabetic macular edema treated by dexamethasone implant: the PREDIAMEX study. Ophthalmol Retina. 2018;2(6):567–573. doi:10.1016/j.oret.2017.10.016
- Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M. Repeated dexamethasone intravitreal implant for the treatment of diabetic macular oedema unresponsive to anti-VEGF therapy: outcome and predictive sd-oct features. J int d’ophtalmologie. 2018;239(4):205–214. doi:10.1159/000485852
- Stewart MW. Diabetic Retinopathy: Current Pharmacologic Treatment and Emerging Strategies. Singapore: ADIS; 2017.
- Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024